
Venture Capitalists Wary of Regulatory Impact on Health Care |
A Duke Clinical Research Institute team including Kevin Schulman, director of Fuqua’s Health Sector Management Program, and Fuqua alumni Larry Diener and Ana Valverde, has some interesting findings on the effects of government policy on funding for health care ventures. Here’s a nice overview from the journal Health Affairs. Federal public policies can have an important impact on the flow of venture capital that helps fuel innovation in biotech, pharmaceuticals, medical devices, and other health care sectors, according to an article by Duke University’s Clay Ackerly and coauthors published today on the Health Affairs Web site. When Ackerly’s team surveyed twenty venture capital fund managers, they found evidence that changes in the level of regulatory and reimbursement risk have “a major impact on the investment strategies of venture capital funds. Approximately two-thirds of respondents said that increases in risk would lead them to shift investments within or across health care sectors or to reduce health care investments altogether,” the researchers report. “Therefore, given venture capital’s important contributions to innovation in health care, policymakers should make a concerted effort to better understand the link between their policy levers and the venture capital industry,” they add. |

This is hardly news – of course Federal regulations have an impact on investment decisions. Public policy should be determined by what is best for citizens, not venture capitalists. The interests of both groups are not always the same!
Other than the occasional displacement of obsolete workers (which isn’t a bad thing), I can’t think of a single scenario where the best interest of the public is not served by the best interest of VCs.